CATT of course tested ranibizumab (Lucentis) as the control against bevacizumab (Avastin) and not aflibercept (Eylea) against bevacizumab (Lucentis).
Apologies. I was too late to edit my above post.
Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024, page-37
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.0¢ |
Change
0.005(1.23%) |
Mkt cap ! $504.7M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 42.0¢ | 40.0¢ | $458.6K | 1.119M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 298731 | 41.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.5¢ | 49490 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |